Bladder Cancer - Results from #180

Evaluation of URO17® to improve non-invasive detection of bladder cancer June 26, 2024

Sequential Intravesical Chemotherapy for Treatment Naïve, High-Risk Non-Muscle Invasive Bladder Cancer: Oncologic Outcomes, Tolerance, and Comparison to Contemporary Controls. June 26, 2024

Frontline immune checkpoint inhibitors in patients ≥ 90 years with advanced urothelial cancer: a single center experience. June 26, 2024

Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors. June 26, 2024

A Safety Net for Safety Net Hospitals: Affiliation with Cancer Centers and Survival Outcomes in Patients with Metastatic Genitourinary Cancers June 25, 2024

Imfinzi Demonstrated Statistically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in NIAGARA Phase III Trial June 25, 2024

Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels. June 25, 2024

Clinical upstaging after neoadjuvant chemotherapy impacting eligibility for vaginal-sparing cystectomy: identifying bladder cancer patients who may benefit from interim imaging. June 25, 2024

Establishing an Intravesical Doublet Chemotherapy Clinic for Nonmuscle-Invasive Bladder Cancer Patients. June 24, 2024

The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. June 24, 2024

Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration. June 24, 2024

Diagnostic Test Accuracy of Urinary DNA Methylation-based Biomarkers for the Detection of Primary and Recurrent Bladder Cancer: A Systematic Review and Meta-analysis. June 21, 2024

CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course. June 21, 2024

Teaching hospitals and textbook outcomes after major urologic cancer surgery. June 21, 2024

Evaluating Antibody-Drug Conjugates Combination with Radiation Therapy in Bladder Cancer - Expert Commentary June 20, 2024

Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis. June 20, 2024

Digital spatial profiling of the microenvironment of muscle invasive bladder cancer. June 20, 2024

NON-ALCOHOLIC FATTY LIVER DISEASE AND EXTRA-HEPATIC CANCER: A NARRATIVE REVIEW. June 20, 2024

Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer. June 20, 2024

Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind? June 19, 2024

Page 10 of 512